Clinical Trials Logo

Filter by:
NCT ID: NCT00567424 Withdrawn - Epilepsy Clinical Trials

GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Start date: July 2006
Phase: Phase 2
Study type: Interventional

Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin

NCT ID: NCT00563238 Withdrawn - Myocardial Ischemia Clinical Trials

Beta-blocker Before Extubation

Start date: November 2007
Phase: N/A
Study type: Interventional

Silent myocardial ischemia is known to occur in the general medical intensive care unit population immediately following tracheal extubation. We believe these patients are at risk for primary cardiac events in the 4 hours immediately following extubation. Metoprolol is a selective beta-1 antagonist, with little to no beta-2 activity at low and moderate doses. The cardioprotective effects of beta blockade have been well documented in randomized controlled trials. In patients undergoing extubation, prophylactic use of intravenous metoprolol may reduce post-extubation ischemia events as well as precursors of cardiogenic pulmonary edema (atrial and ventricular wall tension). Our primary hypothesis is that prophylactic metoprolol (titrated to reduce resting heart rate by at least 10%) prior to tracheal extubation will reduce the rate of ischemia as judged by ST segment analysis.

NCT ID: NCT00562341 Withdrawn - Obesity Clinical Trials

Effect of Lap-Band Induced Weight Loss on Serum PSA Levels

Start date: November 2007
Phase:
Study type: Observational [Patient Registry]

The proposed prospective study aims to determine whether interpretation of PSA levels in morbidly obese men require correction due to the obesity itself. If PSA levels are found to rise after weight loss, interpretation of PSA levels in morbidly obese men may be improved by upward correction of the PSA level. A 'correction factor' may be proposed for the interpretation of PSA levels in obese men, toward the clinical decision regarding indication for prostate biopsy.

NCT ID: NCT00562185 Withdrawn - Ovarian Cancer Clinical Trials

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as doxorubicin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving doxorubicin together with carboplatin may kill more tumor cells. PURPOSE: This phase I and phase II trial is studying the side effects and best dose of carboplatin when given together with doxorubicin to see how well it works in treating patients with recurrent ovarian cancer.

NCT ID: NCT00561366 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

Start date: n/a
Phase: Phase 2
Study type: Interventional

Arimoclomol is a small molecule that upregulates "molecular chaperones" in cells under stress. Arimoclomol extends survival by five weeks when given both pre-symptomatically and at disease onset in a mutant superoxide dismutase (SOD1) transgenic mouse model of ALS. Furthermore, it has been demonstrated to have neuroprotective and neuroregenerative effects in other rat models of nerve damage. Molecular chaperone proteins are critical in the cellular response to stress and protein misfolding. Recent data suggest that the SOD1 mutation responsible for ALS in some patients with familial disease reduces the availability of a variety of molecular chaperones, and thus weakens their ability to respond to cellular stress. Protein misfolding and consequent aggregation may play a role in the pathogenesis of both the familial and sporadic forms of ALS. Therapeutic agents such as arimoclomol that improve cellular chaperone response to protein misfolding may be helpful in ALS.

NCT ID: NCT00560495 Withdrawn - Lung Cancer Clinical Trials

Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Start date: May 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.

NCT ID: NCT00558532 Withdrawn - Clinical trials for Cardiovascular Disease

Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment

Start date: October 2007
Phase: N/A
Study type: Observational

The purpose of this study is to determine the concentration of omega-3 fatty acids in plasma, blood and abdominal fat before and after bariatric surgery to provide guidance for future studies.

NCT ID: NCT00558194 Withdrawn - Obesity Clinical Trials

Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment (Part 2)

Start date: August 2009
Phase: N/A
Study type: Interventional

Behavioral weight loss, the current treatment of choice for moderate obesity, achieves impressive short term results, however, weight regain following treatment is a major problem. Over 50% of participants in behavioral weight loss programs report difficulty with internal antecedents to unhealthy weight control behaviors and this difficulty is associated with weight regain following treatment. Current treatment approaches do not adequately address these antecedents. The aim of this series of studies is to develop, implement, and evaluate a behavioral weight loss program modified to provide participants with skills to deal effectively with affective and cognitive difficulties. The study targets men and women with BMI of 27-40 who self-report difficulty with emotional and/or cognitive antecedents to unhealthy weight control behaviors. The study will randomize 120 participants to receive 12 months of standard behavioral therapy for weight loss or standard behavioral treatment plus affective and cognitive skills training. The long-term goal of this research is to improve the weight loss maintenance outcomes of behavioral weight loss programs by addressing affective and cognitive antecedents to unhealthy weight control behaviors.

NCT ID: NCT00555984 Withdrawn - Brain Neoplasms Clinical Trials

Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors

TIVA
Start date: September 2007
Phase: N/A
Study type: Interventional

If the anesthetic regimen can influence the serum level of inflammatory cytokines and if the levels of cytokines are related to the incidence of post operative complications, these complications may be a function of the anesthetic method. In an effort to find the best anesthetic regimen for patients undergoing craniotomy for intracranial tumors, the researchers will compare the effect of volatile anesthetic with that of total intravenous anesthesia (TIVA) on cytokine levels. The researchers will also compare the composite incidence of some common major post-operative complications after craniotomy for intracranial malignancy.

NCT ID: NCT00555711 Withdrawn - Brain Tumor Clinical Trials

Monitoring Neural Tissues Properties by Modulated Imaging (MI)

MI
Start date: November 2008
Phase:
Study type: Observational

We have developed a safe, non-contact, intra-operative guidance system to optimize tumor resection in neurosurgery. The Modulated Imaging is non-contact optical imaging technology developed at the Beckman Laser Institute, UCI. Compared to other imaging approaches, MI has the unique capability of performing both diffuse optical tomography and rapid, wide-field quantitative mapping of tissue optical properties within a single measurement platform. Preliminary in vivo studies have shown that brain tumors, infiltrating tumor margins and normal brain may have intrinsically different optical properties.